Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 30 | 2026 | 925 | 9.040 |
Why?
|
| Metformin | 4 | 2021 | 166 | 1.890 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 7 | 2026 | 650 | 1.730 |
Why?
|
| Obesity | 8 | 2025 | 2376 | 1.430 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2025 | 331 | 1.270 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2026 | 1408 | 1.100 |
Why?
|
| Glucose | 2 | 2023 | 847 | 1.090 |
Why?
|
| Air Filters | 3 | 2025 | 3 | 1.080 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2019 | 93 | 1.070 |
Why?
|
| Particulate Matter | 3 | 2024 | 91 | 1.070 |
Why?
|
| Pulmonary Emphysema | 3 | 2024 | 95 | 0.970 |
Why?
|
| Environmental Exposure | 3 | 2022 | 290 | 0.960 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2025 | 32 | 0.930 |
Why?
|
| Wildfires | 1 | 2024 | 2 | 0.840 |
Why?
|
| Safety-net Providers | 1 | 2025 | 88 | 0.840 |
Why?
|
| Insulin Resistance | 4 | 2026 | 678 | 0.830 |
Why?
|
| Air Pollution, Indoor | 5 | 2025 | 81 | 0.810 |
Why?
|
| Hyperglycemia | 1 | 2025 | 234 | 0.800 |
Why?
|
| Lung Diseases | 2 | 2025 | 399 | 0.740 |
Why?
|
| Triglycerides | 2 | 2023 | 605 | 0.730 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2024 | 221 | 0.710 |
Why?
|
| Smoking | 3 | 2026 | 926 | 0.710 |
Why?
|
| Schools | 2 | 2022 | 240 | 0.700 |
Why?
|
| Diabetes Mellitus | 2 | 2019 | 886 | 0.690 |
Why?
|
| Cardiovascular Diseases | 2 | 2025 | 2080 | 0.690 |
Why?
|
| Bronchitis, Chronic | 1 | 2021 | 19 | 0.680 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 468 | 0.650 |
Why?
|
| Forced Expiratory Volume | 1 | 2021 | 176 | 0.650 |
Why?
|
| Urban Population | 2 | 2019 | 281 | 0.620 |
Why?
|
| Anti-Asthmatic Agents | 3 | 2025 | 132 | 0.610 |
Why?
|
| Humans | 49 | 2026 | 131322 | 0.610 |
Why?
|
| Smokers | 1 | 2019 | 43 | 0.590 |
Why?
|
| Veterans | 3 | 2025 | 1793 | 0.570 |
Why?
|
| Family Characteristics | 1 | 2019 | 98 | 0.570 |
Why?
|
| Pediatric Obesity | 4 | 2025 | 416 | 0.570 |
Why?
|
| Spirometry | 3 | 2025 | 90 | 0.560 |
Why?
|
| Adult | 17 | 2026 | 31597 | 0.550 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 360 | 0.530 |
Why?
|
| United States | 11 | 2025 | 11761 | 0.530 |
Why?
|
| Middle Aged | 17 | 2026 | 28780 | 0.490 |
Why?
|
| Cohort Studies | 7 | 2025 | 5115 | 0.480 |
Why?
|
| Air Pollutants | 3 | 2022 | 125 | 0.450 |
Why?
|
| Male | 24 | 2026 | 65065 | 0.450 |
Why?
|
| Female | 27 | 2026 | 70976 | 0.450 |
Why?
|
| Lung | 5 | 2026 | 1565 | 0.430 |
Why?
|
| Comorbidity | 4 | 2026 | 1589 | 0.410 |
Why?
|
| Blood Glucose | 3 | 2025 | 1102 | 0.410 |
Why?
|
| Aged | 12 | 2025 | 21192 | 0.400 |
Why?
|
| Primary Health Care | 1 | 2019 | 785 | 0.380 |
Why?
|
| Biomarkers | 5 | 2025 | 3399 | 0.360 |
Why?
|
| Air Pollution | 2 | 2022 | 77 | 0.340 |
Why?
|
| Overweight | 3 | 2025 | 376 | 0.340 |
Why?
|
| Retrospective Studies | 11 | 2025 | 17610 | 0.340 |
Why?
|
| Disease Progression | 6 | 2025 | 2205 | 0.330 |
Why?
|
| Respiratory Function Tests | 2 | 2021 | 220 | 0.320 |
Why?
|
| Respiratory Sounds | 2 | 2022 | 79 | 0.320 |
Why?
|
| Administration, Inhalation | 3 | 2025 | 190 | 0.320 |
Why?
|
| Hospitalization | 4 | 2025 | 1931 | 0.300 |
Why?
|
| Nutrition Surveys | 2 | 2021 | 327 | 0.290 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 4028 | 0.280 |
Why?
|
| Oximetry | 3 | 2023 | 177 | 0.270 |
Why?
|
| Risk Factors | 4 | 2023 | 10940 | 0.260 |
Why?
|
| Uteroglobin | 1 | 2026 | 46 | 0.240 |
Why?
|
| Child | 11 | 2025 | 26211 | 0.230 |
Why?
|
| Hydrocortisone | 1 | 2025 | 224 | 0.220 |
Why?
|
| Treatment Outcome | 5 | 2025 | 12911 | 0.210 |
Why?
|
| Eosinophils | 1 | 2025 | 125 | 0.210 |
Why?
|
| Shock, Septic | 1 | 2025 | 149 | 0.210 |
Why?
|
| Lymphadenopathy | 1 | 2024 | 32 | 0.200 |
Why?
|
| Smoke | 1 | 2024 | 66 | 0.200 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2026 | 232 | 0.200 |
Why?
|
| Emphysema | 1 | 2024 | 67 | 0.190 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2025 | 302 | 0.190 |
Why?
|
| Neck Pain | 1 | 2022 | 20 | 0.190 |
Why?
|
| Achievement | 1 | 2022 | 32 | 0.190 |
Why?
|
| Oxygen | 2 | 2023 | 552 | 0.190 |
Why?
|
| Sarcoidosis | 1 | 2022 | 52 | 0.190 |
Why?
|
| Baltimore | 2 | 2019 | 43 | 0.190 |
Why?
|
| Blast Injuries | 1 | 2022 | 58 | 0.180 |
Why?
|
| Medication Adherence | 1 | 2025 | 333 | 0.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2025 | 496 | 0.180 |
Why?
|
| Dyspnea | 2 | 2022 | 159 | 0.180 |
Why?
|
| Protective Agents | 1 | 2021 | 36 | 0.170 |
Why?
|
| Acute Disease | 1 | 2024 | 1152 | 0.170 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2025 | 712 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 542 | 0.170 |
Why?
|
| Single-Cell Analysis | 1 | 2025 | 370 | 0.170 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2021 | 21 | 0.170 |
Why?
|
| Information Systems | 1 | 2021 | 29 | 0.170 |
Why?
|
| Intensive Care Units | 2 | 2025 | 516 | 0.170 |
Why?
|
| Symptom Assessment | 1 | 2021 | 109 | 0.170 |
Why?
|
| Positive-Pressure Respiration, Intrinsic | 1 | 2020 | 2 | 0.160 |
Why?
|
| Students | 1 | 2022 | 251 | 0.160 |
Why?
|
| Emigrants and Immigrants | 1 | 2022 | 169 | 0.160 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2019 | 21 | 0.150 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 234 | 0.150 |
Why?
|
| Prospective Studies | 3 | 2025 | 6478 | 0.150 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2019 | 81 | 0.140 |
Why?
|
| Propensity Score | 1 | 2019 | 265 | 0.140 |
Why?
|
| Registries | 1 | 2025 | 1598 | 0.140 |
Why?
|
| Cough | 1 | 2018 | 99 | 0.140 |
Why?
|
| Transcriptome | 1 | 2025 | 1164 | 0.140 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 501 | 0.130 |
Why?
|
| Adolescent | 5 | 2025 | 20886 | 0.130 |
Why?
|
| Texas | 1 | 2025 | 3610 | 0.120 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1404 | 0.120 |
Why?
|
| Emergency Service, Hospital | 2 | 2025 | 1210 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 3829 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2019 | 564 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2022 | 666 | 0.110 |
Why?
|
| Inflammation | 1 | 2022 | 1488 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2025 | 3086 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 5264 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2019 | 1221 | 0.110 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6906 | 0.110 |
Why?
|
| Child, Preschool | 3 | 2019 | 15028 | 0.110 |
Why?
|
| Quality of Life | 1 | 2024 | 2100 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2021 | 808 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2025 | 1624 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2018 | 1680 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2982 | 0.090 |
Why?
|
| Tidal Volume | 2 | 2022 | 42 | 0.090 |
Why?
|
| Young Adult | 2 | 2025 | 10074 | 0.080 |
Why?
|
| Prognosis | 1 | 2018 | 4938 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2025 | 1074 | 0.070 |
Why?
|
| Gene Expression Profiling | 2 | 2025 | 1831 | 0.070 |
Why?
|
| Leukocyte Count | 1 | 2025 | 247 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2025 | 135 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2025 | 741 | 0.050 |
Why?
|
| Eosinophilia | 1 | 2025 | 109 | 0.050 |
Why?
|
| Renal Replacement Therapy | 1 | 2025 | 159 | 0.050 |
Why?
|
| Snoring | 1 | 2023 | 16 | 0.050 |
Why?
|
| Iraq | 1 | 2022 | 11 | 0.050 |
Why?
|
| Afghanistan | 1 | 2022 | 17 | 0.050 |
Why?
|
| Environmental Monitoring | 1 | 2021 | 102 | 0.040 |
Why?
|
| Hypoxia | 1 | 2022 | 245 | 0.040 |
Why?
|
| Cigarette Smoking | 1 | 2021 | 80 | 0.040 |
Why?
|
| Peru | 1 | 2020 | 56 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 256 | 0.040 |
Why?
|
| Proteomics | 1 | 2024 | 604 | 0.040 |
Why?
|
| Seasons | 1 | 2021 | 333 | 0.040 |
Why?
|
| Length of Stay | 1 | 2025 | 1393 | 0.040 |
Why?
|
| Animals | 3 | 2026 | 34327 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2022 | 995 | 0.040 |
Why?
|
| Poverty | 1 | 2021 | 455 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 288 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2025 | 2112 | 0.030 |
Why?
|
| Mice | 2 | 2026 | 18471 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1158 | 0.030 |
Why?
|
| Pregnancy | 1 | 2026 | 7567 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2025 | 4664 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 4761 | 0.020 |
Why?
|